Clinical Trial Update: Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) [Phase 3]

View source ↗

Summary

Phase 3 trial MK-3475-811/KEYNOTE-811 evaluating pembrolizumab plus placebo with trastuzumab and chemotherapy in HER2-positive advanced gastric or GEJ adenocarc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• HERCEPTIN (trastuzumab)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma | Phase 3 | Status: COMPLETED | Results posted: 2025-03-17